HIMS
Peptide roulette, but make it bullish
Hims & Hers is back in the market’s good graces, at least for now. Shares jumped after the FDA said it wants its Pharmacy Compounding Advisory Committee to weigh in on whether a dozen peptide drugs can still be compounded — the kind of regulatory question that can make a telehealth stock trade like it just found a cheat code.
Why investors are paying attention
If compounding rules stay friendly, that’s a bigger green light for Hims’ peptide business, which has become one of the company’s juiciest growth narratives. The stock has basically been living off the idea that personalized care + domestic supply chain + popular peptide demand = a very nice equation.
The facility angle isn’t random
Hims also bought a California peptide facility last year, which looks a lot less like a side quest and a lot more like strategic prep work. In plain English: the company wanted more control over supply if U.S. demand keeps climbing and regulators keep debating the rules of the game.
Big picture
This isn’t the same as an FDA approval or a permanent rule change, so don’t start engraving trophies yet. But for a stock that loves a policy tailwind, even a hint that the peptide door stays open can be enough to keep the momentum traders caffeinated.